Wall Street analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to post earnings per share of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.34). Aldeyra Therapeutics also posted earnings of ($0.41) per share during the same quarter last year. The company is scheduled to announce its next earnings report on Wednesday, August 9th.

According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.49) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.41). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.47) to ($1.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Monday, May 15th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.04.

ALDX has been the subject of several recent research reports. HC Wainwright set a $18.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Saturday, April 1st. Canaccord Genuity reiterated a “buy” rating and set a $12.00 target price (down previously from $15.00) on shares of Aldeyra Therapeutics in a research note on Friday, March 31st. Cowen and Company reiterated a “buy” rating and set a $20.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, March 31st. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research note on Friday, March 24th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $16.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, May 31st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Aldeyra Therapeutics presently has an average rating of “Buy” and an average price target of $14.30.

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/21/zacks-brokerages-anticipate-aldeyra-therapeutics-inc-nasdaqaldx-will-announce-earnings-of-0-41-per-share.html.

In other news, major shareholder Life Sciences Maste Perceptive purchased 296,007 shares of the stock in a transaction dated Friday, June 30th. The stock was acquired at an average price of $4.60 per share, for a total transaction of $1,361,632.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 28.40% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in ALDX. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics during the first quarter valued at approximately $132,000. Hikari Power Ltd purchased a new position in Aldeyra Therapeutics during the first quarter valued at approximately $188,000. Sabby Management LLC purchased a new position in Aldeyra Therapeutics during the first quarter valued at approximately $898,000. Sphera Funds Management LTD. raised its position in Aldeyra Therapeutics by 81.4% in the first quarter. Sphera Funds Management LTD. now owns 668,500 shares of the biotechnology company’s stock valued at $3,343,000 after buying an additional 300,000 shares in the last quarter. Finally, Perceptive Advisors LLC raised its position in Aldeyra Therapeutics by 48.7% in the first quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock valued at $12,897,000 after buying an additional 945,000 shares in the last quarter. Institutional investors and hedge funds own 58.25% of the company’s stock.

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) traded down 0.64% on Friday, reaching $4.75. 21,592 shares of the company’s stock traded hands. The stock’s market capitalization is $29.66 million. Aldeyra Therapeutics has a 52 week low of $3.80 and a 52 week high of $8.19. The company has a 50 day moving average of $4.77 and a 200-day moving average of $4.87.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.